Revenue decline of 22% YoY and a 38% drop in the core AlterG segment signal ongoing operational headwinds, partially offset by improved cash burn and a stronger balance sheet. The delayed 10-Q and the massive S-3 overhang (261% of shares outstanding) create uncertainty. Watch for the 10-Q filing and any updates on AlterG order fulfillment in Q2/Q3. The stock is a high-risk micro-cap with a going-concern warning from the prior auditor.
Price Chart
Executive Summary
Lifeward reported Q1 2026 revenue of $3.9M, down 22% YoY from $5.0M, and a GAAP net loss of $10.8M ($6.70/share) vs $4.8M ($5.53/share) a year ago. The headline miss is driven by a $4.9M non-cash acquired in-process R&D charge from the Oratech acquisition, but on an adjusted basis operating loss was flat at $4.6M. Cash burn improved 33% to $3.7M, and the balance sheet was strengthened to $11.4M cash after closing the Oramed strategic transaction and receiving $10M in financing. The 10-Q filing is delayed as the company finalizes accounting for the transaction.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $3.9M, down 22% YoY from $5.0M
- GAAP net loss $10.8M ($6.70/share) vs $4.8M ($5.53/share) YoY; includes $4.9M non-cash acquired in-process R&D charge
- Non-GAAP adjusted operating loss flat at $4.6M YoY
- Cash used in operations improved 33% to $3.7M from $5.5M YoY
- Cash balance increased to $11.4M from $2.2M at Dec 2025, driven by $10M financing and $6.5M cash acquired from Oratech
- ReWalk exoskeleton sales up 11% to $1.6M; AlterG revenue down 38% to $2.1M due to working capital constraints
- 10-Q filing delayed as company finalizes accounting for the strategic transaction
- S-3 filed 18 days ago registers 7.26M shares for resale (~261% of current shares outstanding) from selling shareholders
Financial Impact
Revenue miss of ~33% vs consensus ($3.9M actual vs $5.8M est); GAAP EPS miss of $6.70 vs $-0.34 consensus (driven by one-time charges)
Risk Factors
- Revenue declining 22% YoY with AlterG down 38% due to working capital constraints
- 10-Q filing delay introduces uncertainty and potential compliance risk
- Massive S-3 overhang of 261% of shares outstanding from selling shareholders
- Going-concern warning from prior auditor (substantial doubt)
- Gross margin compression from 42.2% to 34.2% YoY on lower production volumes and tariffs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-002727 |
| Document: zk2635349.htm | 0001178913-26-002727 |
| Document: 0001178913-26-002727-index-headers.html | 0001178913-26-002727 |
| Document: 0001178913-26-002727-index.html | 0001178913-26-002727 |
| Document: 0001178913-26-002727.txt | 0001178913-26-002727 |
| 8-K Data (Synthetic) | 0001178913-26-002727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $7.45 $7.11 | ▼ −4.56% | ▼ −2.57% | $5.85 (−21.48%) |
Aug 14, 2026 7w ago | Press Release | $7.45 $7.11 | ▲ +4.56% | ▲ +2.57% | $5.85 (+21.48%) |
Aug 11, 2026 7w ago | EFFECT | $7.57 $7.40 | ▲ +2.18% | ▲ +1.12% | $5.85 (+22.67%) |
Aug 7, 2026 8w ago | Press Release | $7.69 $6.98 | ▼ −9.17% | ▼ −8.78% | $5.85 (−23.88%) |
May 19, 2026 19w ago | 8-K | $6.40 $6.98 | ▲ +9.06% | ▲ +8.08% | $5.85 (−8.59%) |
May 15, 2026 20w ago | 8-K | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 15, 2026 20w ago | Press Release | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 13, 2026 20w ago | EFFECT | $6.63 $6.80 | ▼ −2.56% | ▼ −3.18% | $5.85 (+11.76%) |
May 11, 2026 20w ago | Press Release | $6.40 $6.98 | ▲ +9.09% | ▲ +9.40% | $5.85 (−8.59%) |
Apr 27, 2026 22w ago | S-3 | $7.09 $6.98 | ▲ +1.55% | ▲ +7.02% | $5.85 (+17.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access